We are excited to share the significant strides we have made through our collaboration with ALZpath, presented at the Tau2024 Global Conference. This partnership marks a pivotal moment in advancing Alzheimer's research, leveraging our innovative Fiber Optic Particle Plasmon Resonance (FOPPR) technology to develop pTau-217 assay.

Essence of the project

Alzheimer's disease is a critical health challenge worldwide, and early, precise detection is key to effective management and treatment. Our research focuses on the detection of pTau-217, a protein variant that serves as a biomarker for Alzheimer's.

Key Achievements

Ultra-Sensitive Detection: The assay demonstrated the ability to detect pTau-217 at levels as low as 2.4 femtograms per milliliter, significantly surpassing existing methods.

Rapid Results: From initial antibody selection to performance validation, the process was completed in just a few days.

We continue to refine our technology and validate its effectiveness across larger clinical cohorts. Our goal is to establish this assay as a standard tool in Alzheimer's diagnostics, contributing to better disease management and improved patient outcomes. We are proud of our collaboration with ALZpath, a leader in Alzheimer's research, and are thrilled to see our technology making a meaningful impact.

Here is our research. To see the PDF file, please click the linked below. 

Tau 2024 Global Conference